Keywords: طرفدار; Follicular lymphoma; Treatment; Obinutuzumab; Idelalisib; Ibrutinib; Venetoclax; Lenalidomide;
مقالات ISI طرفدار (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: طرفدار; Chronic lymphocytic leukemia; CLL; Ibrutinib; Idelalisib; Venetoclax; Targeted therapy;
Keywords: طرفدار; Bortezomib; BTK; Clinical trial; Copanlisib; Ibritumomab tiuxetan; Ibrutinib; Idelalisib; Lenalidomide; Marginal zone lymphoma; Obinutuzumab; PI3K; Radioimmunotherapy; Rituximab; TGR-1202; Ublituximab; Venetoclax;
Keywords: طرفدار; Bendamustine; CLL; Ibrutinib; Idelalisib; Obinutuzumab; Venetoclax;
Keywords: طرفدار; Alemtuzumab; Ibrutinib; Idelalisib; Obinutuzumab; Ofatumumab; Rituximab;
Keywords: طرفدار; ABT-199; delecja 17p; ibrutinib; idelalisib; przewlekła białaczka limfocytowa; wiek biologicznyABT-199; 17p deletion; Ibrutinib; Idelalisib; Chronic lymphocytic leukemia; Biological age
Keywords: طرفدار; Chronic lymphocytic leukemia; Duvelisib; Ibrutinib; Idelalisib; Monoclonal antibodies; Obinutuzumab; Small molecule inhibitors; Venetoclax;
Keywords: طرفدار; Idelalisib; Fludarabine; Lenalidomide; LC-MS/MS; Bioanalytical; Pharmacokinetics
Keywords: طرفدار; ABT-199; Ibrutinib; Idelalisib; Obinutuzumab; Otlertuzumab; CART; ABT-199; Ibrutinib; Idelalisib; Obinutuzumab; Otlertuzumab; CART;
Characterization of the in vitro metabolites of idelalisib in liver microsomes and interspecies comparison
Keywords: طرفدار; Idelalisib; Metabolite characterization; Metabolic pathway; Interspecies comparison;
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies
Keywords: طرفدار; Allogeneic hematopoietic cell transplantation; CLL; Ibrutinib; Idelalisib; Venetoclax;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
Keywords: طرفدار; BCR-ABL kinase inhibitors; Ibrutinib; Idelalisib; Infection; Janus kinase inhibitors; mTOR inhibitors; Small-molecule inhibitors;
Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib
Keywords: طرفدار; Hematologic malignancy; PI3K signaling pathway; Idelalisib; Arsenic trioxide; Apoptosis;
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
Keywords: طرفدار; chronic lymphocytic leukemia; ibrutinib; idelalisib; ofatumumab; indirect treatment comparison;
Front-line treatment of CLL in the era of novel agents
Keywords: طرفدار; Chronic lymphocytic leukaemia; First-line; Bruton's kinase inhibitor; Ibrutinib; Elderly; PI3Kδ inhibitor; Idelalisib; Venetoclax;
Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis
Keywords: طرفدار; Phosphatidylinositol 3-kinase; p110δ; grass pollen; allergen challenge chamber; Vienna Challenge Chamber; idelalisib; GS-1101; CCL17; CCL22; allergic rhinitis; TEAE; Treatment-emergent adverse event; TNNSS; Total nonnasal symptom score; TNSS; Total nasal
Targeted therapies for CLL: Practical issues with the changing treatment paradigm
Keywords: طرفدار; Targeted therapy; Chronic lymphocytic leukemia; Ibrutinib; Idelalisib; Obinutuzumab
Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2016 r – Raport Grupy Roboczej PTHiT i PALG-CLL
Keywords: طرفدار; przewlekła białaczka limfocytowa; analogi puryn; chlorambucyl; przeciwciała monoklonalne; idelalizyb; ibrutynib; wenetoklaksChronic lymphocytic leukemia; Purine nucleoside analogs; Chlorambucil; Monoclonal antibodies; Idelalisib; Ibrutinib; Venetoclax
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia
Keywords: طرفدار; CLL; PI3K; B-cell receptor; Idelalisib; Duvelisib; TGR-1202;
PI3K signaling pathway in normal B cells and indolent B-cell malignancies
Keywords: طرفدار; Chronic lymphocytic leukemia; Indolent non-Hodgkin lymphoma; PI3K; Lymphoma; Leukemia; Idelalisib;
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
Keywords: طرفدار; CLL; PI3K; Idelalisib; Duvelisib
B-cell receptor signaling as a driver of lymphoma development and evolution
Keywords: طرفدار; Ibrutinib; Idelalisib; Lymphoma; B-cell receptor; Antigen;